Enhanced detection. Far-reaching impact.

The BD Onclarity™ HPV Assay provides enhanced high-risk HPV genotyping results beyond 16 and 18 in a single sample-to-result run, positioning your laboratory to adapt to evolving screening guidelines and to provide timely, comprehensive data to clinicians.
Prepare for the changes in HPV genotype prevalence

Vaccination rates and the incidence of cervical adenocarcinoma are both on the rise, making HPV genotype testing an important tool to help stratify risk and guide patient management.

- Genotypes 16 and 18 account for 70% of invasive cancer worldwide, but the prevalence of these genotypes is declining as vaccination rates increase.\(^1\)\(^-\)\(^5\)
- High-risk HPV genotypes 16, 18 and 45 account for 94% of cervical adenocarcinomas.\(^6\)

Be at the forefront of enhanced genotype detection

The BD Onclarity™ HPV Assay has been extensively tested in a clinical trial among over 33,000 women representing different ages, ethnicities and vaccinated and unvaccinated populations.\(^7\)

The assay detects 14 high-risk genotypes.\(^8\)

Enhance laboratory performance

- Support workflow flexibility with an FDA-approved assay offering genotyping for:
  - HPV Primary Screening
  - Co-testing
  - Cytology Primary + ASCUS Reflex

Advance HPV testing accuracy

- Reduced risk of false-positive results due to lack of cross-reactivity with low-risk HPV types.\(^8\)
- Designed to minimize false-negative results by:
  - Including an internal cellular control, ensuring that a sample is present
  - Targeting the E6/E7 region of the HPV viral genome rather than the L1 region, which can be deleted during HPV DNA integration.\(^9\)

Drive laboratory efficiency

- Detect HPV and individually identify genotypes 16, 18 and 45 in only 1 run.\(^8\)
- No additional processing, reagents or hands-on time.\(^8\)

Timely, advanced detection.

Elevate laboratory performance with the BD Onclarity™ HPV Assay.